Global insurance giant MetLife (NYSE: MET) missed Wall Street’s revenue expectations in Q2 CY2026, but sales rose 6.4% year on year to $19.08 billion. Its non-GAAP profit of $2.43 per share was 6.2% above analysts’ consensus estimates.

Is now the time to buy MET? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

MetLife’s second quarter results were marked by broad-based earnings growth, with market participants rewarding the company’s performance as shares rose notably after the announcement. Management attributed the positive momentum to strong underwriting across all segments, increased international sales, and disciplined expense controls. CEO Michel Khalaf pointed to the impact of MetLife’s “New Frontier strategy,” which leverages recurring revenue streams and a diverse global portfolio, emphasizing, “We reported adjusted earnings of approximately $1.6 billion or $2.43 per share.” The quarter also benefited from favorable mortality experience in the Group Benefits segment and continued investment in technology to drive productivity.

Looking ahead, MetLife’s management believes that sustained growth will be driven by continued international expansion, disciplined capital management, and ongoing investment in technology—particularly artificial intelligence. CFO John McCallion noted that the company plans to maintain its expense ratio target even as it integrates higher-cost operations, stating, “We remain confident in our ability to beat our 2026 target of 12.1%.” The company also expects momentum in retirement products and asset management, and management highlighted a robust pipeline for pension risk transfer deals in the second half of the year. However, leaders cautioned that normalization in mortality trends and variability in investment returns could moderate near-term results.

Key Insights from Management’s Remarks

Management credited MetLife’s balanced business model, recurring revenue, and global scale for the quarter’s strong results and outlined several product and segment-specific drivers behind performance.

• Group Benefits underwriting strength: Group Benefits earnings growth was fueled by improved mortality ratios and solid sales, particularly in disability and voluntary product lines. Management cited favorable mortality among working-age populations, but expects normalization over the coming quarters.

• International sales momentum: Asia, Latin America, and EMEA all saw double-digit growth in sales and adjusted earnings. In Asia, product innovation and distribution scale, especially in Korea and Japan, underpinned robust performance, while Latin America benefited from leading positions in several markets and a broad distribution network.

• Expense management and AI productivity: MetLife achieved its direct expense ratio target despite integrating PineBridge Investments, which carries higher structural costs. Management emphasized the role of artificial intelligence in boosting productivity and customer experience, driving efficiency gains beyond the cost of technology investments.

• Retirement and Income Solutions (RIS) pipeline: While first-half pension risk transfer (PRT) activity was lighter, management reported a stronger second-half pipeline and continued growth from U.K. longevity reinsurance and structured settlements, illustrating the resilience and diversification of RIS.

• Shareholder capital return: The company continued to return capital through share buybacks and dividends, with a new $3 billion share repurchase authorization. Management reinforced that capital deployment will remain disciplined, with a focus on organic growth, selective M&A, and maintaining a strong balance sheet.

Drivers of Future Performance

MetLife expects forward momentum to be shaped by international expansion, disciplined capital allocation, and operating leverage from technology investments, while monitoring headwinds from normalization in mortality and investment returns.

• International growth focus: Management sees continued opportunity in Asia and Latin America, supported by demographic trends, product innovation, and multi-channel distribution. In Japan and Korea, balanced sales between U.S. dollar and yen products are expected to maintain growth even amid currency swings.

• Expense discipline and technology leverage: The company aims to keep its direct expense ratio at or below target, using artificial intelligence and digital tools to drive productivity. Management views expense control as critical to offsetting variability in claims and investment income, especially as integration of new businesses like PineBridge continues.

• Retirement and asset management pipeline: MetLife anticipates a pick-up in pension risk transfer activity in the second half of the year, while asset management is expected to benefit from increased institutional client assets and integration benefits. Leaders noted that private equity allocations will modestly decline, but core investment spreads should remain stable within recent guidance ranges.

Catalysts in Upcoming Quarters

In the next few quarters, the StockStory team will monitor (1) the pace of international sales, especially in Asia and Latin America, (2) MetLife’s ability to maintain its direct expense ratio amid ongoing technology investments and acquisitions, and (3) trends in pension risk transfer and asset management flows. We will also watch for any normalization in mortality experience and variability in investment income, which could influence both near-term results and management’s capital deployment strategy.

MetLife currently trades at $99.91, up from $96.26 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

Stocks That Trumped Tariffs

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+214% between June 2020 and June 2025). Find your next big winner with StockStory today.